Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:ATHENASDAQ:COEPNASDAQ:MRNS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.68+2.5%$8.12$6.51▼$13.27$8.96M1.6294,499 shs42,246 shsATHEAlterity Therapeutics$4.37+4.0%$4.11$1.00▼$5.87$37.24M0.8143,431 shs30,405 shsCOEPCoeptis Therapeutics$7.05-6.7%$9.23$2.31▼$13.70$26.57M-0.59118,326 shs47,666 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.83 million shs260 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-2.30%+8.42%+4.83%+10.58%+8.78%ATHEAlterity Therapeutics+3.31%-0.91%+2.82%+22.24%+146.89%COEPCoeptis Therapeutics-6.75%-14.34%-32.28%-25.48%+13.71%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-58.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.343 of 5 stars3.55.00.00.00.00.80.6ATHEAlterity Therapeutics1.4231 of 5 stars3.33.00.00.00.01.70.0COEPCoeptis Therapeutics0.527 of 5 stars0.05.00.00.00.01.70.0MRNSMarinus Pharmaceuticals2.2382 of 5 stars3.20.00.04.20.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00245.82% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00174.60% UpsideCOEPCoeptis Therapeutics 0.00N/AN/AN/AMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K19.99N/AN/A$10.37 per share0.84ATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A1,717.88%-61.65%-49.42%9/1/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)COEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-282.39%-127.23%N/AMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)Latest ADXN, ATHE, MRNS, and COEP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.424.42ATHEAlterity TherapeuticsN/A3.84N/ACOEPCoeptis Therapeutics0.020.820.82MRNSMarinus PharmaceuticalsN/A1.661.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ATHEAlterity Therapeutics2.14%COEPCoeptis Therapeutics13.88%MRNSMarinus Pharmaceuticals98.80%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ATHEAlterity Therapeutics38.80%COEPCoeptis Therapeutics24.25%MRNSMarinus Pharmaceuticals5.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableCOEPCoeptis Therapeutics23.51 million2.66 millionNot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableADXN, ATHE, MRNS, and COEP HeadlinesRecent News About These CompaniesMarinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stockFebruary 11, 2025 | msn.comMarinus Pharmaceuticals director sells shares worth $869January 24, 2025 | msn.comMarinus pharmaceuticals director sells shares for $864January 24, 2025 | msn.comMarinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should KnowJanuary 10, 2025 | zacks.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of ShareholdersJanuary 10, 2025 | stockhouse.comMarinus Pharmaceuticals Inc (MRNS) Stock: Greater Than Its Current Valuation?January 7, 2025 | bovnews.comMARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNSJanuary 6, 2025 | businesswire.comImmedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million DealJanuary 4, 2025 | msn.comMarinus (MRNS) Gets a Hold from Truist FinancialJanuary 4, 2025 | markets.businessinsider.comMarinus Pharmaceuticals Inc (MRNS) Stock: Beyond the Surface of Its Performance?January 4, 2025 | bovnews.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marinus Pharmaceuticals, Inc. BuyoutJanuary 2, 2025 | markets.businessinsider.comMarinus Pharmaceuticals to be acquired by Immedica for 55c per shareJanuary 1, 2025 | finance.yahoo.comMarinus Pharmaceuticals Inc (MRNS) Stock: Understanding Its Underlying ValueDecember 31, 2024 | bovnews.comMarinus Pharma to Be Acquired by Immedica in $30 Million DealDecember 31, 2024 | marketwatch.comImmedica to buy rare disease drugmaker Marinus for $151 millionDecember 31, 2024 | chicagobusiness.comImmedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.December 31, 2024 | finance.yahoo.comImmedica to buy Marinus Pharmaceuticals, stock rises 4%December 31, 2024 | msn.comMarinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%December 30, 2024 | benzinga.comMRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 30, 2024 | businesswire.comShareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public ShareholdersDecember 30, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXN, ATHE, MRNS, and COEP Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.68 +0.22 (+2.54%) Closing price 06/23/2025 03:52 PM EasternExtended Trading$8.15 -0.52 (-5.99%) As of 06/23/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Alterity Therapeutics NASDAQ:ATHE$4.37 +0.17 (+4.05%) Closing price 06/23/2025 03:50 PM EasternExtended Trading$4.37 0.00 (0.00%) As of 06/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Coeptis Therapeutics NASDAQ:COEP$7.05 -0.51 (-6.75%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$7.48 +0.43 (+6.03%) As of 06/23/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
